Abstract
We have exploited the ability of wild-type (wt) p53 to repress gene expression and produce tumor-selective cytotoxicity using viral-directed enzyme prodrug therapy. Vectors containing either the cytomegalovirus or Rous sarcoma virus promoter regulating transcription of a rabbit liver carboxylesterase (CE) have been constructed. Upon transfection of these plasmids into cells expressing either wt or mutant p53, differential expression of the CE has been observed, resulting in sensitization of the cells expressing the latter protein to the anticancer prodrug irinotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carb- onyloxycamptothecin (CPT-11). Transduction of isogenic cell lines with adenovirus containing CE under control of the Rous sarcoma virus promoter confirmed the decreased sensitization of cells expressing wtp53 to CPT-11. These studies indicate that the inactivation of wtp53 by mutant p53 in human tumor cells may be sufficient enough to generate a therapeutic window for enhanced cytotoxicity with CPT-11.
Footnotes
-
This work was supported in part by National Institutes of Health Grants CA66124, CA76202, CA79763, and ES05851; the Cancer Center Core Grant CA21765, and the American Lebanese Syrian Associated Charities.
-
DOI: 10.1124/jpet.102.044149
- Abbreviations:
- bp
- base pair(s)
- mdr
- multidrug resistance
- RSV
- Rous sarcoma virus
- SV40
- simian virus 40
- CE
- carboxylesterase
- wtp53
- wild-type p53
- VDEPT
- viral-directed enzyme prodrug therapy
- CMV
- cytomegalovirus
- tdn
- transdominant
- rCE
- rabbit liver carboxylesterase
- kb
- kilobase(s)
- Received September 6, 2002.
- Accepted October 25, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|